Blockchain Registration Transaction Record

HeartBeam's FDA-Cleared Cable-Free ECG Tech to Debut at JP Morgan Healthcare Conference

HeartBeam announces FDA-cleared cable-free 12-lead ECG technology for arrhythmia assessment, with CEO presenting at JP Morgan 2026 Healthcare Conference ahead of Q1 commercial launch.

This development represents a significant advancement in accessible cardiac care that could transform how heart conditions are monitored and managed. For patients, HeartBeam's portable, cable-free ECG technology means potentially earlier detection of arrhythmias and other cardiac issues without requiring hospital visits, reducing healthcare costs and improving quality of life through convenient at-home monitoring. For healthcare systems, this innovation addresses the growing need for remote patient monitoring solutions that can reduce hospital readmissions and emergency room visits while providing physicians with actionable data between appointments. The technology's FDA clearance and planned commercial launch signal a shift toward more decentralized cardiac care, particularly important as cardiovascular disease remains a leading cause of death globally and telehealth adoption continues to accelerate. By making sophisticated cardiac monitoring more accessible, HeartBeam's technology could help bridge healthcare disparities and improve outcomes for millions of people with cardiac conditions.